Search

Your search keyword '"Camillo Porta"' showing total 13 results
Start Over Author "Camillo Porta" Journal european urology supplements
13 results on '"Camillo Porta"'

1. 97 EVEROLIMUS (EVE) IN RECORD-1 ELDERLY PATIENTS (PTS) WITH METASTATIC RENAL CELL CARCINOMA (MRCC) AND MANAGEMENT OF RELATED ADVERSE EVENTS (AES)

Author

Ulka N. Vaishampayan, Camillo Porta, D. Lebwohl, Bernard Escudier, Susanne Osanto, Emiliano Calvo, Viktor Grünwald, M.A. Climent, Alain Ravaud, W.J. Berg, Robert J. Motzer, Stéphane Oudard, and Sergio Bracarda

Subjects
Oncology, medicine.medical_specialty, Everolimus, business.industry, Renal cell carcinoma, Urology, Internal medicine, medicine, business, medicine.disease, Adverse effect, medicine.drug
Published
2010
Full Text
View/download PDF

2. 719 EVEROLIMUS IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA: SUBGROUP ANALYSIS OF PATIENTS WITH A REDUCTION IN TUMOR BURDEN ENROLLED IN A RANDOMIZED, PLACEBO-CONTROLLED, PHASE II TRIAL

Author

Emiliano Calvo, Viktor Grünwald, Stéphane Oudard, J. Thompson, Robert J. Motzer, Bernard Escudier, Thomas E. Hutson, Sergio Bracarda, Alain Ravaud, E. Kpamegan, Robert A. Figlin, and Camillo Porta

Subjects
Oncology, medicine.medical_specialty, Everolimus, business.industry, Urology, medicine.medical_treatment, Tumor burden, Subgroup analysis, medicine.disease, Placebo, Renal cell carcinoma, Internal medicine, Medicine, In patient, business, Reduction (orthopedic surgery), medicine.drug
Published
2011
Full Text
View/download PDF

3. 94 A REAL-LIFE COMPARATIVE EFFECTIVENESS SIMULATION OF PROGRESSION FREE SURVIVAL COMPARING FIRST-LINE SUNITINIB VS. BEVACIZUMAB + INTERFERON-ALPHA 2A IN METASTATIC RENAL CELL CARCINOMA-CONSIDERING THE EFFECTS OF DOWN-DOSING AND PATIENT COMPLIANCE

Author

G. H. Mickisch, M. Nuijten, J. P. Maroto, S. Walzer, Joaquim Bellmunt, Camillo Porta, Bernard Escudier, and B. Schwander

Subjects
Oncology, medicine.medical_specialty, Bevacizumab, business.industry, Sunitinib, Urology, First line, medicine.disease, Renal cell carcinoma, Internal medicine, medicine, Dosing, Progression-free survival, business, Patient compliance, Interferon Alpha 2a, medicine.drug
Published
2010
Full Text
View/download PDF

4. 257 UPDATED DATA FROM A PHASE 3 TRIAL OF EVEROLIMUS (RAD001) VERSUS PLACEBO IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA

Author

Andrea Kay, Stéphane Oudard, Alain Ravaud, Camillo Porta, Bernard Escudier, Thomas E. Hutson, Norbert Hollaender, Robert A. Figlin, Gladys Urbanowitz, Robert J. Motzer, and Sergio Bracarda

Subjects
Oncology, medicine.medical_specialty, Everolimus, business.industry, Renal cell carcinoma, Urology, Internal medicine, Medicine, In patient, business, medicine.disease, Placebo, medicine.drug
Published
2009
Full Text
View/download PDF

6. 252 RETROSPECTIVE ANALYSIS OF THE SEQUENTIAL USE OF SORAFENIB AND SUNITINIB IN PATIENTS WITH ADVANCED RENAL CELL CARCINOMA (RCC)

Author

Roberto Sabbatini, Valentina Guadalupi, E. Ferraris, Camillo Porta, C. Paglino, I. Chiappino, Emilio Bajetta, G. Procopio, Ilaria Imarisio, A. Bearz, and E. Verzoni

Subjects
Sorafenib, Oncology, medicine.medical_specialty, Sunitinib, business.industry, Urology, medicine.disease, Renal cell carcinoma, Internal medicine, medicine, Retrospective analysis, In patient, business, medicine.drug
Published
2009
Full Text
View/download PDF

7. 247 SUNITINIB IN METASTATIC RENAL CELL CARCINOMA (MRCC) PATIENTS (PTS) WITH BRAIN METASTASES (METS): DATA FROM AN EXPANDED-ACCESS STUDY

Author

Stéphane Oudard, Se-Hoon Lee, Sergio Bracarda, S. Hariharan, Camillo Porta, Martin Gore, G. Carteni, Cezary Szczylik, G.A. Bjarnason, and Robert E. Hawkins

Subjects
Oncology, medicine.medical_specialty, Renal cell carcinoma, Sunitinib, business.industry, Urology, Expanded Access Study, Internal medicine, medicine, medicine.disease, business, medicine.drug
Published
2009
Full Text
View/download PDF

8. 248 SUNITINIB IN PATIENTS (PTS) WITH OR WITHOUT PRIOR NEPHRECTOMY IN AN EXPANDED-ACCESS STUDY OF METASTATIC RENAL CELL CARCINOMA (MRCC)

Author

G.A. Bjarnason, Robert E. Hawkins, G. Carteni, Martin Gore, Camillo Porta, Stéphane Oudard, S.H. Kee, Cezary Szczylik, Sergio Bracarda, and S. Hariharan

Subjects
Oncology, medicine.medical_specialty, Sunitinib, business.industry, Urology, Expanded Access Study, medicine.medical_treatment, medicine.disease, Nephrectomy, Renal cell carcinoma, Internal medicine, medicine, In patient, business, medicine.drug
Published
2009
Full Text
View/download PDF

10. SAFETY AND EFFICACY OF SUNITINIB IN AN EXPANDED-ACCESS TRIAL OF METASTATIC RENAL CELL CARCINOMA (MRCC): UPDATED RESULTS AND SUBPOPULATION ANALYSIS

Author

G. A. Bjarnason, Se-Hoon Lee, Sergio Bracarda, Cezary Szczylik, Stéphane Oudard, Wilfried Eberhardt, Robert E. Hawkins, M. E. Gore, Camillo Porta, and G. Carteni

Subjects
Oncology, medicine.medical_specialty, Sunitinib, Renal cell carcinoma, business.industry, Urology, Internal medicine, medicine, Expanded access trial, medicine.disease, business, medicine.drug
Published
2008
Full Text
View/download PDF

11. SORAFENIB IN ADVANCED RENAL CELL CARCINOMA (RCC): SURVIVAL AND BIOMARKER RESULTS FROM A PHASE III TRIAL

Author

Carol Peña, Walter M. Stadler, Bernard Escudier, Timothy Eisen, Ronit Simantov, D. Heng, M. Shan, Camillo Porta, J. Elting, Cezary Szczylik, and Ronald M. Bukowski

Subjects
Oncology, Sorafenib, medicine.medical_specialty, Renal cell carcinoma, business.industry, Urology, Internal medicine, medicine, Biomarker (medicine), medicine.disease, business, medicine.drug
Published
2008
Full Text
View/download PDF

12. SORAFENIB PLUS INTERFERON-α2A IN METASTATIC RENAL CELL CARCINOMA: RESULTS FROM RAPSODY (GOIRC STUDY 0681), A RANDOMISED PROSPECTIVE PHASE II TRIAL OF TWO DIFFERENT TREATMENT SCHEDULES

Author

L. Mentuccia, A. Contu, Sergio Bracarda, Corrado Boni, Camillo Porta, Fabrizio Artioli, V. De Angelis, Donatello Gasparro, Antonella Santoro, and Claudia Caserta

Subjects
Oncology, Sorafenib, medicine.medical_specialty, Interferon α2a, business.industry, Renal cell carcinoma, Urology, Internal medicine, Medicine, business, medicine.disease, medicine.drug
Published
2008
Full Text
View/download PDF

13. 856 SORAFENIB IN PATIENTS WITH ADVANCED RENAL CELL CARCINOMA (RCC) AND PRIOR CYTOKINE THERAPY: SUBGROUP ANALYSIS OF TARGETS

Author

D. Me Dermott, Sibyl Anderson, Camillo Porta, Sylvie Negrier, M. Moore, Ronit Simantov, Joaquim Bellmunt, Ronald M. Bukowski, Bernard Escudier, Marc-Oliver Grimm, and E. Jäger

Subjects
Sorafenib, Oncology, medicine.medical_specialty, Cytokine Therapy, business.industry, Urology, Subgroup analysis, medicine.disease, Renal cell carcinoma, Internal medicine, medicine, In patient, business, medicine.drug
Published
2007
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results